

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPIC
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRSEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:10:20 ON 28 MAY 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:10:30 ON 28 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAY 2008 HIGHEST RN 1023132-78-6

DICTIONARY FILE UPDATES: 27 MAY 2008 HIGHEST RN 1023132-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10573525.str



```

chain nodes :
10 19 22 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
2-10 10-11 15-24
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-2 1-5 2-3 3-4 15-24
exact bonds :
2-10 10-11
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

```

G1:H,O,X,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:Atom 20:Atom 22:CLASS
23:Atom 24:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,O,X,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:10:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:10:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 176 TO ITERATE

100.0% PROCESSED 176 ITERATIONS 107 ANSWERS
SEARCH TIME: 00.00.01

L3 107 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 09:11:03 ON 28 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 27 May 2008 (20080527/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 full

L4 4 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300447 CAPLUS

DOCUMENT NUMBER: 142:373838

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004276015	A1	20050407	AU 2004-276015	20040930
CA 2540083	A1	20050407	CA 2004-2540083	20040930
EP 1675854	A1	20060705	EP 2004-787263	20040930
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1856491	A	20061101	CN 2004-80027592	20040930
BR 2004014972	A	20061107	BR 2004-14972	20040930
JP 2007507467	T	20070329	JP 2006-530264	20040930
NO 2006001344	A	20060324	NO 2006-1344	20060324
MX 2006PA03349	A	20060608	MX 2006-PA3349	20060324
US 20070043073	A1	20070222	US 2006-573484	20060324
IN 2006MN00475	A	20070316	IN 2006-MN475	20060424
PRIORITY APPLN. INFO.:			EP 2003-22053	A 20031001
			WO 2004-EP52378	W 20040930
OTHER SOURCE(S):		CASREACT 142:373838; MARPAT 142:373838		
GI				




I




II

- AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed $-\log IC_{50}$ values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.
- IT 849357-47-7P 849357-48-8P 849357-49-9P
 849357-50-2P 849357-51-3P 849357-52-4P
 849357-54-6P 849357-55-7P 849357-56-8P
 849357-57-9P 849357-58-0P 849357-59-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
- RN 849357-47-7 CAPLUS
- CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (CA INDEX NAME)




- RN 849357-48-8 CAPLUS
- CN Benzenesulfonamide, N,N-diethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-

imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849357-49-9 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849357-50-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849357-51-3 CAPLUS

CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849357-52-4 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 849357-54-6 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849357-55-7 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849357-56-8 CAPLUS

CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849357-57-9 CAPLUS

CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849357-58-0 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-59-1 CAPLUS

CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300446 CAPLUS

DOCUMENT NUMBER: 142:373837

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276014	A1	20050407	AU 2004-276014	20040930
CA 2540243	A1	20050407	CA 2004-2540243	20040930
EP 1670796	A1	20060621	EP 2004-787262	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856495	A	20061101	CN 2004-80027833	20040930
BR 2004014933	A	20061107	BR 2004-14933	20040930
JP 2007507466	T	20070329	JP 2006-530263	20040930
NO 2006001317	A	20060323	NO 2006-1317	20060323
MX 2006PA03351	A	20060608	MX 2006-PA3351	20060324
US 20060293302	A1	20061228	US 2006-573202	20060324
US 7279488	B2	20071009		
IN 2006MN00362	A	20070615	IN 2006-MN362	20060331
US 20080021039	A1	20080124	US 2007-905033	20070927
PRIORITY APPLN. INFO.:			EP 2003-22046	A 20031001
			WO 2004-EP52377	W 20040930
			US 2006-573202	A1 20060324

OTHER SOURCE(S): CASREACT 142:373837; MARPAT 142:373837

GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzene-sulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849530-66-1P 849530-68-3P 849530-70-7P
 849530-72-9P 849530-74-1P 849530-76-3P
 849530-78-5P 849530-80-9P 849530-82-1P
 849530-84-3P 849530-86-5P 849530-88-7P
 849530-90-1P 849530-92-3P 849530-94-5P
 849530-96-7P 849530-98-9P 849531-00-6P
 849531-02-8P 849531-04-0P 849531-06-2P
 849531-08-4P 849531-10-8P 849531-12-0P
 849531-14-2P 849531-16-4P 849531-18-6P
 849531-20-0P 849531-23-3P 849531-25-5P
 849531-27-7P 849531-29-9P 849531-31-3P
 849531-33-5P 849531-36-8P 849531-38-0P
 849531-40-4P 849531-42-6P 849531-44-8P
 849531-46-0P 849531-48-2P 849531-50-6P
 849531-52-8P 849531-54-0P 849531-56-2P
 849531-58-4P 849531-60-8P 849531-62-0P
 849531-64-2P 849531-66-4P 849531-68-6P
 849531-70-0P 849531-72-2P 849531-74-4P
 849531-76-6P 849531-78-8P 849531-80-2P
 849531-82-4P 849531-84-6P 849531-86-8P
 849531-88-0P 849531-90-4P 849531-92-6P
 849531-94-8P 849531-96-0P 849531-98-2P


849532-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)


RN 849530-66-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849530-68-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[[4-(phenylmethyl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 849530-70-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[[4-(phenyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849530-72-9 CAPLUS

CN Benzonitrile, 4-[4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 849530-74-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[[4-(4-methylphenyl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 849530-76-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[[4-(2,4-dimethylphenyl)-1-piperazinyl]sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849530-78-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[[4-(3,5-dichlorophenyl)-1-piperazinyl]sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849530-80-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849530-82-1 CAPLUS

CN Ethanone, 1-[4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 849530-84-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(4-morpholinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 849530-86-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849530-88-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(4-methyl-1-piperidiny)lsulfonyl]phenyl]- (CA INDEX NAME)




RN 849530-90-1 CAPLUS


CN Methanone, [1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-piperidiny]phenyl- (CA INDEX NAME)




RN 849530-92-3 CAPLUS
 CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 849530-94-5 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 849530-96-7 CAPLUS
 CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 849530-98-9 CAPLUS
 CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-00-6 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-02-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 849531-04-0 CAPLUS

CN Benzenesulfonamide, N-cyclohexyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-06-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 849531-08-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethyl)- (CA INDEX NAME)




RN 849531-10-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N,3-trimethyl- (CA INDEX NAME)




RN 849531-12-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-phenyl- (CA INDEX NAME)




RN 849531-14-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 849531-16-4 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-18-6 CAPLUS

CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-20-0 CAPLUS

CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849531-23-3 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(2-phenylethyl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)




RN 849531-25-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-27-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-[(2,6-dimethylphenyl)-1-piperazinyl]sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-29-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(4-(2-methylphenyl)-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849531-31-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849531-33-5 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(1-piperidylsulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-36-8 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 849531-38-0 CAPLUS

CN Isoquinoline, 6,7-diethoxy-1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 849531-40-4 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 849531-42-6 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 6-[3-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-44-8 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 6-[3-chloro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-46-0 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 6-[2-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-48-2 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 849531-50-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-phenyl- (CA INDEX NAME)




RN 849531-52-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849531-54-0 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (CA INDEX NAME)




RN 849531-56-2 CAPLUS

CN 5H-1,4-Diazepin-5-one, 4-ethylhexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 849531-58-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(2-methylphenyl)- (CA INDEX NAME)




RN 849531-60-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-pyridinyl)- (CA INDEX NAME)




RN 849531-62-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-methylphenyl)- (CA INDEX NAME)




RN 849531-64-2 CAPLUS


CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849531-66-4 CAPLUS
 CN Benzenesulfonamide, N-(2-fluoro-4-methylphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-68-6 CAPLUS
 CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-70-0 CAPLUS
 CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)




RN 849531-72-2 CAPLUS
 CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(2-methylphenyl)- (CA INDEX NAME)




RN 849531-74-4 CAPLUS

CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-76-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-78-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-(1-azetidinyisulfonyl)phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849531-80-2 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-82-4 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-84-6 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 849531-86-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-88-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-6-[4-(1-piperidinylsulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-90-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-6-[4-(4-morpholinesulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-92-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[4-(1-azetidinesulfonyl)phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl- (CA INDEX NAME)




RN 849531-94-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(4-thiomorpholinesulfonyl)phenyl]- (CA INDEX NAME)




RN 849531-96-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-[(1-oxido-4-thiomorpholinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 849531-98-2 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 6-[4-[(1,1-dioxido-4-thiomorpholinyl)sulfonyl]phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 849532-00-9 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300445 CAPLUS

DOCUMENT NUMBER: 142:373836

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Marx, Degenhard; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030769	A1	20050407	WO 2004-EP52376	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276013	A1	20050407	AU 2004-276013	20040930
CA 2540242	A1	20050407	CA 2004-2540242	20040930
EP 1673371	A1	20060628	EP 2004-787261	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856494	A	20061101	CN 2004-80027819	20040930
BR 2004014873	A	20061212	BR 2004-14873	20040930
JP 2007507465	T	20070329	JP 2006-530262	20040930
NO 2006001316	A	20060323	NO 2006-1316	20060323
MX 2006PA03554	A	20060605	MX 2006-PA3554	20060329
IN 2006MN00473	A	20070316	IN 2006-MN473	20060424
PRIORITY APPLN. INFO.:			EP 2003-22064	A 20031001
			WO 2004-EP52376	W 20040930

OTHER SOURCE(S): CASREACT 142:373836; MARPAT 142:373836

GI




I




II

- AB Title compds. I [R1 = alkoxy; A = alkylene; R2 = H, halo, alkyl, alkoxy; Het = (un)substituted monocyclic or fused 5-10 membered (un)saturated heteroaryl containing 1-3 heteroatoms selected from N, O, and S] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 2-furanylboronic acid. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values from 6.61 up to 7.61 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.
- IT 849356-71-4P 849356-72-5P 849356-73-6P
 849356-74-7P 849356-75-8P 849356-76-9P
 849356-77-0P 849356-78-1P 849356-79-2P
 849356-80-5P 849356-81-6P 849356-82-7P
 849356-83-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)
- RN 849356-71-4 CAPLUS
- CN 3H-Imidazo[4,5-b]pyridine, 6-(2-furanyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




- RN 849356-72-5 CAPLUS
- CN 3H-Imidazo[4,5-b]pyridine, 6-(3-furanyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-73-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 849356-74-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-thienyl)- (CA INDEX NAME)




RN 849356-75-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-thienyl)- (CA INDEX NAME)




RN 849356-76-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-(1H-indol-5-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-77-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-(1H-benzimidazol-2-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-78-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(6-methyl-1H-benzimidazol-2-yl)- (CA INDEX NAME)




RN 849356-79-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-3-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-80-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-(2-benzofuranyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-81-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-2-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 849356-82-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-methyl-2-thienyl)- (CA INDEX NAME)



RN 849356-83-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-phenyl-2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:777790 CAPLUS

DOCUMENT NUMBER: 139:292156

TITLE: Preparation of alkoxypyridines as inducible nitric oxide synthase (iNOS) inhibitors

INVENTOR(S): Boer, Rainer; Marx, Degenhard; Eltze, Manfrid; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480385	A1	20031002	CA 2003-2480385	20030325
AU 2003226706	A1	20031008	AU 2003-226706	20030325
EP 1490366	A1	20041229	EP 2003-744851	20030325
EP 1490366	B1	20080123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008785	A	20050111	BR 2003-8785	20030325
CN 1642955	A	20050720	CN 2003-806917	20030325
JP 2005525388	T	20050825	JP 2003-578361	20030325
NZ 535959	A	20060526	NZ 2003-535959	20030325
AT 384722	T	20080215	AT 2003-744851	20030325
IN 2004MN00462	A	20050218	IN 2004-MN462	20040820
MX 2004PA09283	A	20050125	MX 2004-PA9283	20040923
US 20050171125	A1	20050804	US 2004-509396	20040924
US 7138399	B2	20061121		
ZA 2004007766	A	20060628	ZA 2004-7766	20040927
NO 2004004633	A	20041223	NO 2004-4633	20041027
HK 1078850	A1	20071109	HK 2005-110611	20051123
PRIORITY APPLN. INFO.:			EP 2002-7049	A 20020327
			WO 2003-EP3076	W 20030325

OTHER SOURCE(S): MARPAT 139:292156

GI



- AB Title compds. I [wherein R1 = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC50 (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).
- IT 608880-74-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-aminophenyl)-3H-imidazo[4,5-b]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (inducible NO-synthase inhibitor; preparation of alkoxy pyridines as inducible NO-synthase inhibitors)
- RN 608880-74-6 CAPLUS
- CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




- IT 608880-57-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridine 608880-62-2P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-dichlorophenyl)-3H-imidazo[4,5-b]pyridine 608880-63-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-bromophenyl)-3H-imidazo[4,5-b]pyridine 608880-72-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-p-tolyl-3H-imidazo[4,5-b]pyridine 608880-73-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine 608880-75-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-hydroxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-76-8P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-[4-(N,N-dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridine 608880-77-9P, 2-[2-(4-Methoxypyridin-2-

yl)ethyl]-6-(4-trifluoromethylphenyl)-3H-imidazo[4,5-b]pyridine
 608880-78-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-
 dimethoxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-79-1P,
 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-benzyloxyphenyl)-3H-imidazo[4,5-
 b]pyridine 608880-80-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-
 benzyloxy-3-fluorophenyl)-3H-imidazo[4,5-b]pyridine 608880-81-5P
 , 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-cyanophenyl)-3H-imidazo[4,5-
 b]pyridine 608880-83-7P, N-[4-[2-[2-(4-Methoxypyridin-2-
 yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]acetamide
 608880-84-8P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-
 imidazo[4,5-b]pyridin-6-yl]phenyl]benzenesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(inducible NO-synthase inhibitor; preparation of alkoxy pyridines as
 inducible NO-synthase inhibitors)


RN 608880-57-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-phenyl-
 (CA INDEX NAME)




RN 608880-62-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-(3,4-dichlorophenyl)-2-[2-(4-methoxy-2-
 pyridinyl)ethyl]- (CA INDEX NAME)




RN 608880-63-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-(4-bromophenyl)-2-[2-(4-methoxy-2-
 pyridinyl)ethyl]- (CA INDEX NAME)




RN 608880-72-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-
 methylphenyl)- (CA INDEX NAME)




RN 608880-73-5 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 608880-75-7 CAPLUS

CN Phenol, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 608880-76-8 CAPLUS

CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 608880-77-9 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 608880-78-0 CAPLUS

CN 3H-imidazo[4,5-b]pyridine, 6-(3,4-dimethoxyphenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 608880-79-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 608880-80-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 6-[3-fluoro-4-(phenylmethoxy)phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 608880-81-5 CAPLUS

CN Benzonitrile, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)




RN 608880-83-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 608880-84-8 CAPLUS

CN Benzenesulfonamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.04

206.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

STN INTERNATIONAL LOGOFF AT 09:18:52 ON 28 MAY 2008